alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 34 studies by Li Z (page 1 of 2) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 34 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Journal of Alzheimer's disease : JAD 2024-01-01

CSF p-tau181 and p-tau231 biomarkers distinguished AD, MCI, and healthy populations. 2 key findings →

Participants: 5,017 Evidence: low

Full summary, score breakdown and related studies → Original source

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Acta neuropathologica 2017-02-28

More than 20 genetic loci have been associated with risk for Alzheimer's disease (AD), but reported genome-wide significant loci do not account for all the estimated heritability and provide little information about underlying biological mechanisms. 5 key findings →

Design: case-control study Participants: 3,146 Evidence: moderate

Full summary, score breakdown and related studies → Original source

An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Nature neuroscience 2019-10-07

Parietal cortex RNA-sequencing (RNA-seq) data were generated from individuals with and without Alzheimer disease (AD; n control = 13; n AD = 83) from the Knight Alzheimer Disease Research Center (Knight ADRC). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Alzheimer's Research & Therapy 2024-12-23

Compared with non-users, SGLT-2i, GLP-1RA, TZD and metformin were associated with the reduced risk of dementia in patients with T2D. SGLT-2i, and GLP-1RA may serve as the optimal choice to improve the cognitive prognosis in patients with T2D. 5 key findings →

Design: meta-analysis Participants: 3,462,926 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Molecular Neurodegeneration 2025-10-29

Plasma GFAP and pTau biomarkers (pTau181, pTau231, pTau217) are significantly elevated in Aβ-positive individuals, with stronger Aβ–pTau associations observed in APOE ε4 carriers (CPAS: β = 0.26, p = 0.003 for pTau231; ADNI: β = 0.45, p < 0.001 for pTau181). 5 key findings →

Design: cohort Participants: 806 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology and therapy 2021-08-16

These results indicate that trans-resveratrol has potential neuroprotective roles in the treatment of moderate to mild AD and that its mechanism may involve a reduction in the accumulation and toxicity of Aβ in the brain of patients, thereby reducing neuroinflammation. 4 key findings →

Design: case-control study Participants: 15 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Green tea improves cognitive function through reducing AD-pathology and improving anti-oxidative stress capacity in Chinese middle-aged and elderly people

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in aging neuroscience 2022-08-05

In the tea-consuming group, the MoCA scores ( P = 0.000), Hopkins Verbal Learning Test (HVLT) immediate recall ( P = 0.012) and delayed recall ( P = 0.013) were significantly higher while Trail Making Test-B ( P = 0.005) and Victoria Stroop test interference ( P = 0.000) were lower. 5 key findings →

Participants: 264 Evidence: low

Full summary, score breakdown and related studies → Original source

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 55 out of 100. BMC neurology 2019-02-09

Currently there are no disease-modifying treatments for Parkinson's disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. 4 key findings →

Participants: 75 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Molecular neurodegeneration 2019-05-08

Low frequency coding variants in TREM2 are associated with Alzheimer disease (AD) risk and cerebrospinal fluid (CSF) TREM2 protein levels are different between AD cases and controls. 4 key findings →

Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Developing a machine learning model for detecting depression, anxiety, and apathy in older adults with mild cognitive impairment using speech and facial expressions: A cross-sectional observational study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. International journal of nursing studies 2023-07-07

The machine learning model developed in this study demonstrated strong classification performance in detecting and differentiating depression, anxiety, and apathy. 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature communications 2020-09-04

The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovascular dysfunction in neurodegenerative diseases remain elusive. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review

✓ Peer-reviewed alzhub usefulness score 50 out of 100. BMC neurology 2025-07-07

During lecanemab treatment for AD, it is essential to fully understand the mechanisms, imaging characteristics, and management strategies of ARIA. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of hematology & oncology 2022-08-28

Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

US Health Care Spending by Payer and Health Condition, 1996-2016

✓ Peer-reviewed alzhub usefulness score 47 out of 100. JAMA 2020-03-01

Total health care spending increased from an estimated $1.4 trillion in 1996 (13.3% of gross domestic product [GDP]; $5259 per person) to an estimated $3.1 trillion in 2016 (17.9% of GDP; $9655 per person); 85.2% of that spending was included in this study. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Cellular & molecular immunology 2024-06-28

Metabolic changes play a crucial role in determining the status and function of macrophages, but how lipid reprogramming in macrophages contributes to tumor progression is not yet fully understood. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer's Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2020-11-23

It accounts for a quarter of the elderly population and is associated with cognitive decline. 4 key findings →

Participants: 111 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Annals of neurology 2015-03-02

Growing evidence indicates that the activation of c-Jun N-terminal kinase (JNK) is implicated in the multiple major pathological features of Alzheimer disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed